Bora Pharmaceuticals, a CDMO specializing in complex oral solid dosage, liquids, ophthalmics, nasal sprays, and semi-solids pharmaceutical products, opened a new facility in Taoyuan City, Taiwan, to provide an extensive range of ophthalmic manufacturing services. 

The 6,891 square meter facility is equipped with the latest technological advancements and will specialize in manufacturing ophthalmic products such as sterile solutions, emulsions, creams, ointments, and gels.

Bora’s Taoyuan City facility received FDA approval earlier this year and will include two tube and two solutions lines.

“The average age of adults aged 60-plus is expected to double by 2050, and, as a result of the aging population, we’ve seen demand for ophthalmic products skyrocket in markets across the globe,” said Bobby Sheng, CEO of Bora Pharmaceuticals. “The opening of the new ophthalmic site marks a significant milestone in our commitment to deliver excellence for our clients and providing services that are high in demand. Since the site launched, we have received numerous requests from new clients who are particularly interested in our ophthalmic service.

The new center of excellence will give highly skilled operators access to the latest technology to manufacture and package an extensive range of products.